Key result
High histologic grade was associated with poorer overall survival in patients with primary angiosarcoma of the breast (P=0.01), and adjuvant therapy provided no observed additional benefit.
Cohort (n=16)
No
Answers are grounded in this paper and cite their sources.
Primary angiosarcoma of the breast is a highly aggressive malignancy where high histologic grade predicts poorer overall survival, and adjuvant therapy did not demonstrate additional benefit in this small cohort.
BACKGROUND: Primary angiosarcoma of breast (PAOB) is a rare and highly aggressive malignancy. There is no general agreement on optimal treatments or prognostic factors for this orphan disease. The objective of this study was to investigate the clinicopathologic features and management experiences of PAOB. METHODS: We performed a retrospective review of medical and pathologic records of 17 consecutive patients diagnosed with PAOB between January 2000 and February 2014 at FuDan University Shanghai Cancer Center. We evaluated the clinical characteristics, multimodality treatments, and associated clinical outcomes. RESULTS: A total of 16 patients were included in this retrospective study (median age at PAOB presentation 33.5 years, range: 19-56 years). Palpable tumor with or without breast skin ecchymosis presented as the most common initial symptom. All patients underwent surgery with curative intent. Median disease-free survival and overall survival (OS) were 9 months and 13.6 months, respectively. One-year and 3-year disease-free survival rates were 43.8% and 6.3%, with OS rates of 93.8% and 78.1%, respectively. High histologic grade indicated poorer OS by univariate analysis (P=0.01). However, neither adjuvant chemotherapy nor radiotherapy contributed to clinical outcomes in our series. CONCLUSION: PAOB is considered as an infrequent breast neoplasm with aggressive characteristics. Histologic grade and early metastasis (within 12 months after diagnosis) are associated with poor prognosis. Regardless of grade, additional benefit was not observed with adjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2015) conducted a cohort in Primary angiosarcoma of breast (n=16). High histologic grade vs. Lower histologic grade was evaluated on Overall survival (p=0.01). High histologic grade was associated with poorer overall survival in patients with primary angiosarcoma of the breast (P=0.01), and adjuvant therapy provided no observed additional benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: